MindRank reports 10% weight loss on oral GLP-1 drug in phase 2b
MindRank has shared the skinny on its oral GLP-1 receptor agonist, publishing data from a Chinese phase 2b obesity trial that suggests efficacy is in the same ballpark as Eli Lilly’s orforglipron.
